LivaNova PLC: Strategy/Company/Operations
6 July 2016
LivaNova PLC (the “Company” or “LivaNova”) announces that, on 6 July 2016, LivaNova filed with the U.S. Securities and Exchange Commission its Current Report on Form 8-K, a copy of which can be found at www.sec.gov.
A copy of the Form 8-K is being submitted to the UK Listing Authority via the National Storage Mechanism and will shortly be available for inspection at: http://www.morningstar.co.uk/uk/nsm.
LivaNova PLC, headquartered in London, UK, is a global medical technology company formed by the merger of Sorin S.p.A, a leader in the treatment of cardiovascular diseases, and Cyberonics, Inc., a medical device company with core expertise in neuromodulation. LivaNova transforms medical innovation into meaningful solutions for the benefit of patients, healthcare professionals, and healthcare systems. The Company employs approximately 4,600 employees worldwide. With a presence in more than 100 countries, LivaNova operates as three business units: Cardiac Rhythm Management, Cardiac Surgery, and Neuromodulation, with operating headquarters in Clamart (France), Mirandola (Italy) and Houston (U.S.), respectively.
LivaNova is listed on NASDAQ and listed on the Official List of the UK’s Financial Conduct Authority and traded on London Stock Exchange (LSE) under the ticker symbol “LIVN”.For more information, please visit www.livanova.com, or contact:
Investor Relations and Media
Vice President, Investor Relations & Corporate Communications
Phone: +1 (281) 228-7262
Fax: +1 (281) 218-9332